Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Intramuscular Personalized Neoantigen Peptide Vaccine in Advanced Melanoma and Renal Cell Carcinoma
TCTR20191003001Phase 1Completed
- Sponsor
- Chulalongkorn University
- Start
- Jan 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma and renal cell carcinoma (RCC), sponsored by Chulalongkorn University. Started Jan 2021; status: completed.
02
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on TCTR20191003001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20191003001.